Efficacy and safety of subcutaneous immunotherapy with polymerized allergen mixtures in polyallergic patients. ARES observational study.

Allergen mixtures Allergic rhinitis Allergic rhinoconjunctivitis Polyallergy Polymerized extracts

Journal

Expert review of clinical immunology
ISSN: 1744-8409
Titre abrégé: Expert Rev Clin Immunol
Pays: England
ID NLM: 101271248

Informations de publication

Date de publication:
27 Jun 2024
Historique:
medline: 27 6 2024
pubmed: 27 6 2024
entrez: 27 6 2024
Statut: aheadofprint

Résumé

Administrationof allergen mixtures of many components comprises the most common approach forAmerican allergists regarding the management of polyallergic patients. Europeanallergists, however, are more reluctant to this type of treatment due to thepotential drawbacks of mixing extracts. To assess theefficacy and safety of subcutaneous immunotherapy (SCIT) with polymerizedallergen mixtures without dilutional effect in polyallergic patients.Thisobservational, prospective, multicenter study included patients (between 5-60 years) with respiratory allergic diseases that had been prescribed with SCITwith mixtures of two pollen or mite extracts. Changesin Symptoms and Medication Score (SMS) and in rhinitis quality of life questionnaire (RQLQ), subjective clinicalimprovement, treatment satisfaction and tolerability were assessed after the1-year treatment. 115 patientswere included in the assessment. Mean global SMS decreased from 3.5 (SD = 1.1) to1.6 (SD = 1.2) points, with a meanabsolute reduction of 1.6 (SD = 1.3) points in the RQLQ score ( SCIT with polymerizedallergen mixtures from either pollen or mite extracts proved to be an effectiveand safe treatment option for polyallergic patients suffering from allergicrespiratory diseases.

Sections du résumé

BACKGROUND UNASSIGNED
Administrationof allergen mixtures of many components comprises the most common approach forAmerican allergists regarding the management of polyallergic patients. Europeanallergists, however, are more reluctant to this type of treatment due to thepotential drawbacks of mixing extracts.
RESEARCH DESIGNAND METHODS UNASSIGNED
To assess theefficacy and safety of subcutaneous immunotherapy (SCIT) with polymerizedallergen mixtures without dilutional effect in polyallergic patients.Thisobservational, prospective, multicenter study included patients (between 5-60 years) with respiratory allergic diseases that had been prescribed with SCITwith mixtures of two pollen or mite extracts. Changesin Symptoms and Medication Score (SMS) and in rhinitis quality of life questionnaire (RQLQ), subjective clinicalimprovement, treatment satisfaction and tolerability were assessed after the1-year treatment.
RESULTS UNASSIGNED
115 patientswere included in the assessment. Mean global SMS decreased from 3.5 (SD = 1.1) to1.6 (SD = 1.2) points, with a meanabsolute reduction of 1.6 (SD = 1.3) points in the RQLQ score (
CONCLUSION UNASSIGNED
SCIT with polymerizedallergen mixtures from either pollen or mite extracts proved to be an effectiveand safe treatment option for polyallergic patients suffering from allergicrespiratory diseases.

Identifiants

pubmed: 38934292
doi: 10.1080/1744666X.2024.2373886
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Marcela Santaolalla (M)

Allergy department, Hospital Universitario HM Sanchinarro, Madrid, Spain.

José Arias-Irigoyen (J)

Allergy unit, Clínica Dr. Arias Irigoyen, Huelva, Andalusia, Spain().

Jose Miguel Soler (JM)

Allergy and Clinical Immunology Unit, ALLERCEN, Barcelona, Catalonia, Spain().

José María Duque (JM)

Allergy unit, MEDICUR Sevilla, Seville, Andalusia, Spain.

Rosario Escudero (R)

Allergy department, Fundación Hospital Calahorra, Calahorra, La Rioja), Spain(.

José Luis Pérez-Formoso (JL)

Allergy unit, Clínica Dr. Formoso, Seville, Andalusia, Spain().

Teófilo Lobera (T)

Allergy department, CAR San Millán, Logroño, La Rioja, Spain().

María Rueda (M)

Allergy department, Hospital Quirónsalud Barcelona, Barcelona, Catalonia, Spain().

César Alias (C)

Allergy unit, Centre Assitencial Baix Llobregat, Cornellà de Llobregat, Catalonia, Spain().

Helena Hermida (H)

Allergy unit, Policlínica Augusta, Badalona, Catalonia, Spain().

Catalina Vela (C)

Allergy unit, Logroño Promosalud, Logroño, La Rioja, Spain().

Leire Begoña (L)

Medical Department, ROXALL Medicina España S.A, Zamudio, Basque Country, Spain().

Alexander Vázquez (A)

Medical Department, ROXALL Medicina España S.A, Zamudio, Basque Country, Spain().

Begoña Madariaga (B)

Medical Department, ROXALL Medicina España S.A, Zamudio, Basque Country, Spain().

Classifications MeSH